Roche and Ionis Report Positive Late-Stage Trial Results for Kidney Drug
Ionis Pharmaceuticals (IONS) and Roche (RHHBY) announced positive interim results from a late-stage trial of their RNA-targeting therapy, sefaxersen. The drug met its primary endpoint in treating patients with primary IgA nephropathy, an autoimmune kidney disorder. This marks the first time such a treatment has shown success at this stage for the condition. The once-monthly injectable medication is being developed to reduce proteinuria and slow disease progression. Both companies are now expected to advance toward regulatory submissions based on these findings. The results could position sefaxersen as a potential breakthrough therapy in nephrology, offering new hope for patients with limited treatment options. This development may lead to increased investor confidence in both Ionis Pharmaceuticals and Roche due to the promising clinical outcome.
